Laurion Capital Management’s Vor Biopharma VOR Stock Holding History

Laurion Capital Management’s Portfolio VOR Stock Details VOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$5.69M	Buy	318,670 +1,427	+0.4%	+$20.1K	0.25%	113
2025 Q4	$4.15M	Buy	+317,243	New	+$5.91M	0.15%	83
2024 Q4	–	Sell	-1,449	Closed	-$20.3K	–	390
2024 Q3	$20.3K	Sell	1,449 -124,823	-99%	-$2.28M	﹤0.01%	265
2024 Q2	$2.53M	Sell	126,272 -32,872	-21%	-$1.06M	0.03%	203
2024 Q1	$7.54M	Hold	159,144	–	–	0.06%	219
2023 Q4	$7.16M	Hold	159,144	–	–	0.06%	217
2023 Q3	$6.75M	Hold	159,144	–	–	0.04%	251
2023 Q2	$9.84M	Hold	159,144	–	–	0.06%	217
2023 Q1	$17.1M	Hold	159,144	–	–	0.12%	161
2022 Q4	$21.2M	Buy	159,144 +116,279	+271%	+$11.5M	0.1%	171
2022 Q3	$3.41M	Hold	42,865	–	–	0.02%	286
2022 Q2	$4.26M	Hold	42,865	–	–	0.07%	179
2022 Q1	$5.18M	Hold	42,865	–	–	0.06%	162
2021 Q4	$9.96M	Buy	42,865 +10,000	+30%	+$2.88M	0.1%	133
2021 Q3	$10.3M	Buy	32,865 +3,582	+12%	+$1.06M	0.04%	268
2021 Q2	$10.9M	Hold	29,283	–	–	0.06%	204
2021 Q1	$25.2M	Buy	+29,283	New	+$24.8M	0.14%	148

Other funds holding VOR

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Laurion Capital Management's VOR Position: Q1 2026 in Review

Laurion Capital Management increased its Vor Biopharma (VOR) stake by 0.45% in Q1 2026, buying an estimated $20.1K and bringing the position to 318,670 shares worth $5.69M. The position accounts for 0.25% of the portfolio, ranked #113.

Laurion Capital Management first reported a position in VOR in Q1 2021 and has held it in 17 quarters since. The position peaked at $25.2M in Q1 2021. 80 funds tracked by Wall St. Rank hold VOR as of Q1 2026.

Laurion Capital Management held 318,670 shares of Vor Biopharma worth $5.69M as of Q1 2026.
Laurion Capital Management bought 1,427 Vor Biopharma shares in Q1 2026, an estimated $20.1K.
Vor Biopharma made up 0.25% of Laurion Capital Management's portfolio in Q1 2026, its #113 holding.
Laurion Capital Management first reported a position in Vor Biopharma in Q1 2021 and has held it in 17 quarters since.
Laurion Capital Management's Vor Biopharma position peaked at $25.2M in Q1 2021.
80 funds tracked by Wall St. Rank held Vor Biopharma as of Q1 2026.

Based on Laurion Capital Management's 13F filing for Q1 2026, filed 14 May 2026.